|Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses|
JM Lee, JL Hays, CM Annunziata, AM Noonan, L Minasian, JA Zujewski, ...
JNCI: Journal of the National Cancer Institute 106 (6), 2014
|Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers|
KB Kuchenbaecker, L McGuffog, D Barrowdale, A Lee, P Soucy, S Healey, ...
JNCI: Journal of the National Cancer Institute 109 (7), 2017
|The role of PARP inhibitors in the treatment of gynecologic malignancies|
RE Reinbolt, JL Hays
Frontiers in oncology 3, 237, 2013
|Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target|
U Saini, S Naidu, AC ElNaggar, HK Bid, JJ Wallbillich, K Bixel, C Bolyard, ...
Oncogene 36 (2), 168-181, 2017
|Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions|
DH Moon, JM Lee, AM Noonan, CM Annunziata, L Minasian, N Houston, ...
British journal of cancer 109 (4), 1072-1078, 2013
|Akt activation mediates acquired resistance to fibroblast growth factor receptor inhibitor BGJ398|
J Datta, S Damodaran, H Parks, C Ocrainiciuc, J Miya, L Yu, EP Gardner, ...
Molecular cancer therapeutics 16 (4), 614-624, 2017
|Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers|
KB Kuchenbaecker, SL Neuhausen, M Robson, D Barrowdale, ...
Breast cancer research 16 (6), 1-27, 2014
|Olaparib in the management of ovarian cancer|
K Bixel, JL Hays
Pharmacogenomics and personalized medicine 8, 127, 2015
|Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma|
MA Krook, A Lenyo, M Wilberding, H Barker, M Dantuono, KM Bailey, ...
Molecular cancer therapeutics 19 (3), 847-857, 2020
|Use of targeted therapeutics in epithelial ovarian cancer: a review of current literature and future directions|
MH Vetter, JL Hays
Clinical Therapeutics 40 (3), 361-371, 2018
|Mixed adeno-neuroendocrine carcinoma: an aggressive clinical entity|
S Brathwaite, J Rock, MM Yearsley, T Bekaii-Saab, L Wei, WL Frankel, ...
Annals of surgical oncology 23 (7), 2281-2286, 2016
|A microfluidic chip enables isolation of exosomes and establishment of their protein profiles and associated signaling pathways in ovarian cancer|
KDP Dorayappan, ML Gardner, CL Hisey, RA Zingarelli, BQ Smith, ...
Cancer research 79 (13), 3503-3513, 2019
|A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety|
JL Hays, G Kim, A Walker, CM Annunziata, JM Lee, J Squires, N Houston, ...
Molecular and clinical oncology 1 (3), 565-569, 2013
|Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer|
JM Lee, JL Hays, VL Chiou, CM Annunziata, EM Swisher, MI Harrell, ...
Oncotarget 8 (45), 79175, 2017
|Appendiceal mixed adeno-neuroendocrine carcinoma: a population-based study of the Surveillance, Epidemiology, and End Results registry|
S Brathwaite, MM Yearsley, T Bekaii-Saab, L Wei, CR Schmidt, ...
Frontiers in oncology 6, 148, 2016
|Distinct functions of retinoic acid receptor beta isoforms: implications for targeted therapy|
CB Swift, JL Hays, WJ Petty
Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug …, 2008
|Oligomerization-induced modulation of TPR-MET tyrosine kinase activity|
JL Hays, SJ Watowich
Journal of Biological Chemistry 278 (30), 27456-27463, 2003
|Feasibility and safety of sequential research‐related tumor core biopsies in clinical trials|
J Lee, JL Hays, AM Noonan, J Squires, L Minasian, C Annunziata, ...
Cancer 119 (7), 1357-1364, 2013
|Autophagy induction results in enhanced anoikis resistance in models of peritoneal disease|
JL Chen, J David, D Cook-Spaeth, S Casey, D Cohen, K Selvendiran, ...
Molecular Cancer Research 15 (1), 26-34, 2017
|PARP inhibition and gynecologic malignancies: a review of current literature and on-going trials|
SM Crafton, K Bixel, JL Hays
Gynecologic oncology 142 (3), 588-596, 2016